Expand chart
Data: Company documents; Chart: Andrew Witherspoon/Axios

Over the past 4 years, the product that generated the most sales for Pfizer wasn't one of its household names, like Lyrica, Lipitor or Viagra. It was Prevnar 13, a vaccine that protects against pneumonia and other infections.

The bottom line: Pfizer has collected $23.4 billion in Prevnar 13 sales since 2015, including $5.8 billion last year. The pharmaceutical giant got a big revenue boost in 2015, after the federal government recommended the vaccine for people older than 65 and required insurance to cover it.

Details: Before 2015, most of Pfizer's Prevnar 13 revenue came from international markets.

  • But the seal of approval from the Centers for Disease Control and Prevention in late 2014 prompted U.S. seniors to get the vaccine, which most commonly was given to children younger than 2.
  • Pfizer commands higher prices for the drug in the U.S. The price of a single Prevnar 13 shot this year, before taking out rebates and discounts, is about $195 — a 5% increase from 2018 and 79% higher than its list price from 2010.
  • The patent for Prevnar 13 doesn't expire until 2026, several years after some of Pfizer's other growing medications, like Ibrance and Xeljanz, will have lost their patent protection. (Lyrica, Lipitor and Viagra are already off-patent.)

Go deeper: The rising price of the pneumococcal vaccine is angering doctors, Kaiser Health News reports.

Go deeper

The CIA's new license to cyberattack

Illustration: Aïda Amer/Axios

In 2018 President Trump granted the Central Intelligence Agency expansive legal authorities to carry out covert actions in cyberspace, providing the agency with powers it has sought since the George W. Bush administration, former U.S. officials directly familiar with the matter told Yahoo News.

Why it matters: The CIA has conducted disruptive covert cyber operations against Iran and Russia since the signing of this presidential finding, said former officials.

1 hour ago - Technology

Tech hits the brakes on office reopenings

Illustration: Annelise Capossela/Axios

Tech was the first industry to send its workers home when COVID-19 first hit the U.S., and it has been among the most cautious in bringing workers back. Even still, many companies are realizing that their reopening plans from as recently as a few weeks ago are now too optimistic.

Why it matters: Crafting reopening plans gave tech firms a chance to bolster their leadership and model the beginnings of a path back to normalcy for other office workers. Their decision to pause those plans is the latest sign that normalcy is likely to remain elusive in the U.S.

The existential threat to small business

Illustration: Eniola Odetunde/Axios

The coronavirus pandemic has changed the game for U.S. businesses, pushing forward years-long shifts in workplaces, technology and buying habits and forcing small businesses to fight just to survive.

Why it matters: These changes are providing an almost insurmountable advantage to big companies, which are positioned to come out of the recession stronger and with greater market share than ever.